- Home
- BRTX vs MYNZ Comparison
BRTX vs MYNZ Comparison
Compare BRTX & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRTX | MYNZ |
|---|---|---|
| Founded | 1997 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 8.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BRTX | MYNZ |
|---|---|---|
| Price | $1.14 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 33.5K | ★ 200.2K |
| Earning Date | 11-12-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $383,400.00 | ★ $659,935.00 |
| Revenue This Year | $112.14 | N/A |
| Revenue Next Year | $139.81 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.70 | N/A |
| 52 Week Low | $0.98 | $0.92 |
| 52 Week High | $2.55 | $8.20 |
Technical Indicators
Market Signals| Indicator | BRTX | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 51.69 | 48.15 |
| Support Level | $1.00 | $1.09 |
| Resistance Level | $1.21 | $1.21 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 78.26 | 42.25 |
Price Performance
Historical ComparisonAbout BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.